CG
KRYS icon

Cutler Group’s Krystal Biotech KRYS Stock Holding History

Cutler Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$6K Buy
+400
New +$55.6K ﹤0.01% 1505
2022
Q1 		– Sell
-56,500
Closed -$236K – 5700
2021
Q4 		$236K Buy
56,500
+27,700
+96% +$1.61M 0.01% 1187
2021
Q3 		$486K Buy
+28,800
New +$1.7M 0.02% 805

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cutler Group's KRYS Position: Q1 2024 in Review

Cutler Group sold out of Krystal Biotech (KRYS) in Q1 2024, closing a stake of 200 shares — an estimated $27.8K sold.

Cutler Group first reported a position in KRYS in Q4 2021 and held it in 9 quarters. The position peaked at $606K in Q4 2021. 234 funds tracked by Wall St. Rank hold KRYS as of Q1 2024.

  • Cutler Group reported no remaining Krystal Biotech position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 200 Krystal Biotech shares in Q1 2024, an estimated $27.8K.
  • Cutler Group first reported a position in Krystal Biotech in Q4 2021 and held it in 9 quarters.
  • Cutler Group's Krystal Biotech position peaked at $606K in Q4 2021.
  • 234 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.